|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2010-6-1
|
|
pubmed:abstractText |
Common variable immunodeficiency disorders (CVIDs) are the most common forms of symptomatic primary antibody failure in adults and children. Replacement immunoglobulin is the standard treatment, although there are few consistent data on optimal dosages and target trough IgG levels required for infection prevention.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
1097-6825
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright (c) 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
125
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1354-1360.e4
|
|
pubmed:dateRevised |
2011-7-19
|
|
pubmed:meshHeading |
pubmed-meshheading:20471071-Adolescent,
pubmed-meshheading:20471071-Adult,
pubmed-meshheading:20471071-Aged,
pubmed-meshheading:20471071-Bacterial Infections,
pubmed-meshheading:20471071-Bronchiectasis,
pubmed-meshheading:20471071-Common Variable Immunodeficiency,
pubmed-meshheading:20471071-Disease-Free Survival,
pubmed-meshheading:20471071-Female,
pubmed-meshheading:20471071-Follow-Up Studies,
pubmed-meshheading:20471071-Humans,
pubmed-meshheading:20471071-Immunoglobulins, Intravenous,
pubmed-meshheading:20471071-Immunotherapy,
pubmed-meshheading:20471071-Male,
pubmed-meshheading:20471071-Middle Aged,
pubmed-meshheading:20471071-Prospective Studies,
pubmed-meshheading:20471071-Splenomegaly,
pubmed-meshheading:20471071-Tomography, X-Ray Computed,
pubmed-meshheading:20471071-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years.
|
|
pubmed:affiliation |
Department of Clinical Immunology, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
